Biosafety Evaluation Services for Cardiovascular Implant Materials

Since cardiovascular implants need to be implanted in the body for a long period of time, evaluating the potential toxic effects they may cause is an essential step in cardiovascular implant research. Ace Therapeutics is committed to providing biosafety evaluation services for implanted materials.

Importance of Biosafety Assessment of Cardiovascular Implants

Unlike chemicals and pharmaceuticals, cardiovascular implants are composed of complex materials, including the raw materials used in the manufacture of the implant, impurities introduced during the production process, additives, chemical additives, and small molecules and fine particulates matter resulting from physical abrasion or chemical decomposition. Therefore, cardiovascular implants require not only a toxicity evaluation of the raw materials used in their production, but also a full and complete biosafety evaluation of the final product that has been designed and finalized for production.

Fig. 1 The underlying mechanisms of drug-eluting stents restenosis. (Hu W, and Jiang J, 2022)

Ace Therapeutics has years of research experience in cardiovascular implant biosafety research and we are able to provide customized biosafety evaluation studies of cardiovascular implant materials.

Systemic Toxicity Evaluation Services for Cardiovascular Implant Materials

We are able to provide systemic toxicity testing services for cardiovascular implant materials in mice or rats.

• Acute Toxicity Tests
• Sub-acute Toxicity Tests
• Sub-chronic Toxicity Tests
• Chronic Toxicity Tests

Genotoxicity Evaluation Services for Cardiovascular Implant Materials

Since cardiovascular implants (materials) are long-term internal implantable devices, it may also be necessary to examine the genotoxicity of cardiovascular implant materials to the body. We can provide the following genotoxicity testing services for cardiovascular implant materials:

• Chromosomal Aberration Tests
• Ames Tests
• Micronucleus Tests

Carcinogenicity Evaluation Services for Cardiovascular Implant Materials

Because cardiovascular implants are in direct contact with the cardiovascular system and the bloodstream for long periods of time, it is necessary to evaluate the potential carcinogenicity of the implanted materials. We can provide our clients with carcinogenicity evaluation services to observe the potential carcinogenicity of cardiovascular implants and materials throughout the lifespan of experimental animals.

Ace Therapeutics is committed to providing biosafety evaluation services to help researchers obtain biosafety data on cardiovascular implant materials. If you are interested in our services for cardiovascular implant biosafety evaluation, please do not hesitate to contact us.

1. Hu, W.; Jiang, J. Hypersensitivity and in-stent restenosis in coronary stent materials. Front Bioeng Biotechnol. 2022, 10: 1003322.